tetano
Editor, Senior Moderator
Front Immunol
. 2023 May 24;14:1195299.
doi: 10.3389/fimmu.2023.1195299. eCollection 2023. SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern
Qinhai Ma[SUP] 1 [/SUP], Man Li[SUP] 2 [/SUP], Lin Ma[SUP] 3 [/SUP], Caroline Zhang[SUP] 3 [/SUP], Hong Zhang[SUP] 2 [/SUP], Huiling Zhong[SUP] 2 [/SUP], Jian Wen[SUP] 3 [/SUP], Yongsheng Wang[SUP] 2 [/SUP], Zewei Yan[SUP] 2 [/SUP], Wei Xiong[SUP] 3 [/SUP], Linping Wu[SUP] 4 [/SUP], Jianmin Guo[SUP] 5 [/SUP], Wei Yang[SUP] 5 [/SUP], Zifeng Yang[SUP] 1 6 [/SUP], Biliang Zhang[SUP] 1 2 4 [/SUP]
Affiliations
Introduction: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has rapidly spread around the globe. With a substantial number of mutations in its Spike protein, the SARS-CoV-2 Omicron variant is prone to immune evasion and led to the reduced efficacy of approved vaccines. Thus, emerging variants have brought new challenges to the prevention of COVID-19 and updated vaccines are urgently needed to provide better protection against the Omicron variant or other highly mutated variants.
Materials and methods: Here, we developed a novel bivalent mRNA vaccine, RBMRNA-405, comprising a 1:1 mix of mRNAs encoding both Delta-derived and Omicron-derived Spike proteins. We evaluated the immunogenicity of RBMRNA-405 in BALB/c mice and compared the antibody response and prophylactic efficacy induced by monovalent Delta or Omicron-specific vaccine with the bivalent RBMRNA-405 vaccine in the SARSCoV-2 variant challenge.
Results: Results showed that the RBMRNA-405 vaccine could generate broader neutralizing antibody responses against both Wuhan-Hu-1 and other SARS-CoV-2 variants, including Delta, Omicron, Alpha, Beta, and Gamma. RBMRNA-405 efficiently blocked infectious viral replication and lung injury in both Omicron- and Delta-challenged K18-ACE2 mice.
Conclusion: Our data suggest that RBMRNA-405 is a promising bivalent SARS-CoV-2 vaccine with broad-spectrum efficacy for further clinical development.
Keywords: SARS-CoV-2; bivalent mRNA vaccine; broad-spectrum efficacy; immunogenicity; variants of concern (VOCs).
. 2023 May 24;14:1195299.
doi: 10.3389/fimmu.2023.1195299. eCollection 2023. SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern
Qinhai Ma[SUP] 1 [/SUP], Man Li[SUP] 2 [/SUP], Lin Ma[SUP] 3 [/SUP], Caroline Zhang[SUP] 3 [/SUP], Hong Zhang[SUP] 2 [/SUP], Huiling Zhong[SUP] 2 [/SUP], Jian Wen[SUP] 3 [/SUP], Yongsheng Wang[SUP] 2 [/SUP], Zewei Yan[SUP] 2 [/SUP], Wei Xiong[SUP] 3 [/SUP], Linping Wu[SUP] 4 [/SUP], Jianmin Guo[SUP] 5 [/SUP], Wei Yang[SUP] 5 [/SUP], Zifeng Yang[SUP] 1 6 [/SUP], Biliang Zhang[SUP] 1 2 4 [/SUP]
Affiliations
- PMID: 37292197
- PMCID: PMC10244545
- DOI: 10.3389/fimmu.2023.1195299
Introduction: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has rapidly spread around the globe. With a substantial number of mutations in its Spike protein, the SARS-CoV-2 Omicron variant is prone to immune evasion and led to the reduced efficacy of approved vaccines. Thus, emerging variants have brought new challenges to the prevention of COVID-19 and updated vaccines are urgently needed to provide better protection against the Omicron variant or other highly mutated variants.
Materials and methods: Here, we developed a novel bivalent mRNA vaccine, RBMRNA-405, comprising a 1:1 mix of mRNAs encoding both Delta-derived and Omicron-derived Spike proteins. We evaluated the immunogenicity of RBMRNA-405 in BALB/c mice and compared the antibody response and prophylactic efficacy induced by monovalent Delta or Omicron-specific vaccine with the bivalent RBMRNA-405 vaccine in the SARSCoV-2 variant challenge.
Results: Results showed that the RBMRNA-405 vaccine could generate broader neutralizing antibody responses against both Wuhan-Hu-1 and other SARS-CoV-2 variants, including Delta, Omicron, Alpha, Beta, and Gamma. RBMRNA-405 efficiently blocked infectious viral replication and lung injury in both Omicron- and Delta-challenged K18-ACE2 mice.
Conclusion: Our data suggest that RBMRNA-405 is a promising bivalent SARS-CoV-2 vaccine with broad-spectrum efficacy for further clinical development.
Keywords: SARS-CoV-2; bivalent mRNA vaccine; broad-spectrum efficacy; immunogenicity; variants of concern (VOCs).